Cancer/testis antigen 1 (91-101)

Cancer/testis antigen 1; NY-ESO-1

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.

CAT No: ta-494

Synonyms/Alias:Cancer/testis antigen 1 (91-101); NY-ESO-1 (91-101)

Custom Peptide Synthesis
cGMP Peptide
  • Registration of APIs
  • CMC information required for an IND
  • IND and NDA support
  • Drug master files (DMF) filing
Sequence
YLAMPFATPME
Areas of Interest
Antigen-presenting Cells; Cancer Research

Cancer/testis antigen 1 (91-101) is a synthetic peptide fragment derived from the well-characterized cancer/testis antigen 1 (CTAG1), also known as NY-ESO-1. This nonapeptide represents a specific epitope region within the larger antigen, which is notable for its restricted expression in normal testicular tissue and a broad range of malignancies. Its unique biochemical profile and immunogenic properties have made it a focal point in tumor immunology, epitope mapping, and antigen presentation studies. Researchers value this peptide as a defined tool for dissecting cellular immune recognition mechanisms and for evaluating T cell responses in cancer-related investigations.

Immunological assay development: The 91-101 epitope of CTAG1 serves as a critical reagent for the development and optimization of immunological assays, including ELISPOT, intracellular cytokine staining, and flow cytometry-based detection of antigen-specific T cells. Its defined amino acid sequence allows for precise stimulation of cytotoxic T lymphocytes (CTLs) in vitro, facilitating the quantification and characterization of immune responses against tumor-associated antigens. Utilizing this peptide in assay systems enables researchers to monitor antigen-specific cellular immunity in preclinical models and patient-derived samples, advancing the understanding of tumor immunosurveillance.

Epitope mapping and validation: As a well-defined peptide segment, the 91-101 region is instrumental in mapping T cell epitopes within the CTAG1 protein. Its use in epitope validation studies provides insights into the minimal recognition motifs required for T cell activation. By systematically analyzing T cell responses to this peptide, investigators can delineate the immunodominant regions of the antigen, guiding the rational design of peptide-based vaccines and immunotherapeutic strategies targeting cancer/testis antigens.

Antigen presentation research: The peptide is widely utilized to explore the mechanisms of major histocompatibility complex (MHC) class I antigen processing and presentation. By pulsing antigen-presenting cells with the 91-101 sequence, researchers can investigate peptide loading efficiency, MHC-peptide stability, and subsequent T cell recognition events. These studies contribute to a deeper understanding of how tumor antigens are processed and displayed to the immune system, informing the development of more effective immunomodulatory approaches.

T cell receptor specificity studies: The defined nature of the CTAG1 (91-101) peptide enables its application in evaluating the specificity and avidity of T cell receptors (TCRs) recognizing cancer/testis antigens. By employing this peptide in functional assays, researchers can characterize TCR-peptide-MHC interactions, assess cross-reactivity with related epitopes, and identify high-affinity TCRs suitable for adoptive cell transfer protocols in experimental settings. Such studies provide essential data for the engineering of T cells with enhanced anti-tumor activity.

Peptide-based screening platforms: The 91-101 peptide is a valuable component in high-throughput screening platforms designed to identify novel immunomodulatory compounds or antibodies that interact with CTAG1-derived epitopes. Incorporation of this peptide into multiplexed arrays or binding assays allows for the systematic evaluation of candidate molecules that may modulate antigen-specific immune responses. This application supports the discovery and preclinical validation of next-generation immunotherapeutic agents in oncology research.

Source#
Homo sapiens (human)
Epitope
91-101
Restricting HLA
HLA-A24
References
Eikawa; Int J Cancer 2013

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Featured Services
Peptide Modification ServicesEpitope Mapping ServicescGMP Peptide ServiceCustom Conjugation ServicePeptide Analysis ServicesPeptide Synthesis ServicesPeptide CDMOPeptide Nucleic Acids Synthesis
Hot Products
About us

Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.

From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.

Our Customers

Creative Peptides customer logo 1 Creative Peptides customer logo 2 Creative Peptides customer logo 3 Creative Peptides customer logo 4 Creative Peptides customer logo 5 Creative Peptides customer logo 6 Creative Peptides customer logo 7 Creative Peptides customer logo 8 Creative Peptides customer logo 9 Creative Peptides customer logo 10 Creative Peptides customer logo 11 Creative Peptides customer logo 12 Creative Peptides customer logo 13 Creative Peptides customer logo 14 Creative Peptides customer logo 15 Creative Peptides customer logo 16 Creative Peptides customer logo 17 Creative Peptides customer logo 18 Creative Peptides customer logo 19 Creative Peptides customer logo 20 Creative Peptides customer logo 21 Creative Peptides customer logo 22 Creative Peptides customer logo 23 Creative Peptides customer logo 24 Creative Peptides client partner 1 Creative Peptides client partner 2 Creative Peptides client partner 3 Creative Peptides client partner 4 Creative Peptides client partner 5 Creative Peptides client partner 6 Creative Peptides client partner 7 Creative Peptides client partner 8 Creative Peptides client partner 9 Creative Peptides client partner 10 Creative Peptides client partner 11 Creative Peptides client partner 12 Creative Peptides client partner 13 Creative Peptides client partner 14 Creative Peptides client partner 15 Creative Peptides client partner 16 Creative Peptides client partner 17 Creative Peptides client partner 18 Creative Peptides client partner 19 Creative Peptides client partner 20 Creative Peptides client partner 21 Creative Peptides client partner 22 Creative Peptides client partner 23 Creative Peptides client partner 24